Commentary: considerations on the pharmacotherapy of attention deficits and hyperactivity in children with autism and other pervasive developmental disorders.
Nicolson
R
R
Child Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland, USA.
Castellanos
F X
FX
D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications* / Q000188:drug therapy*; D001321:Autistic Disorder / Q000150:complications; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000150:complications*; D002675:Child, Preschool; D006801:Humans; D011619:Psychotropic Drugs / Q000627:therapeutic use*
D011619:Psychotropic Drugs